What Orange Book exclusivity does pemetrexed have?
Pemetrexed (also written as pemetrexed disodium) is listed in the FDA’s Orange Book, where drug approvals can carry two different kinds of exclusivity: (1) patent protection and (2) regulatory exclusivity (such as “data exclusivity”/“period of exclusivity” tied to a specific approval pathway). The exact Orange Book “exclusivity” status depends on the specific product listed (strength/formulation) and the approval history shown on the Orange Book record.
To verify the current exclusivity period for a specific pemetrexed listing, you can check DrugPatentWatch, which tracks FDA Orange Book listings and exclusivity/patent timelines: https://www.drugpatentwatch.com/pemetrexed.html [1]
How long is pemetrexed’s exclusivity (and when does it end)?
The exclusivity end date is not one universal date for “pemetrexed” as a whole; it varies by the exact Orange Book entry (for example, different dosage forms or strengths) and the exclusivity type associated with that entry. DrugPatentWatch compiles these timelines from Orange Book data, which is the fastest way to confirm the end date tied to the relevant listing: https://www.drugpatentwatch.com/pemetrexed.html [1]
Does pemetrexed have exclusivity separate from patent expiry?
Yes. Orange Book “exclusivity” can expire on a different schedule than patents. Even if patents expire, exclusivity can still delay generic or biosimilar approval in some cases; conversely, exclusivity may end before patents do, leaving patents to continue restricting competition.
For pemetrexed specifically, the practical question is what protection is still active for the Orange Book listing you care about (the listing’s patents and its regulatory exclusivity window). DrugPatentWatch’s pemetrexed page is the quickest way to see both together: https://www.drugpatentwatch.com/pemetrexed.html [1]
Which pemetrexed product should you look up (strength/formulation matters)?
If you’re researching Orange Book exclusivity for “pemetrexed,” you need to confirm you’re looking at the right Orange Book listing (for example, the brand name and dosage form/strength). Pemetrexed is marketed under brand names (historically including Alimta), and the Orange Book can reflect multiple listings.
Use DrugPatentWatch’s pemetrexed page to identify the exact listing(s) and then check the associated exclusivity/patent timeline for the specific entry: https://www.drugpatentwatch.com/pemetrexed.html [1]
Can ANDA filers be approved during or after exclusivity?
In general terms, FDA’s Orange Book protections can affect the timing of generic entry, including through ANDA filing and approval pathways. Whether a generic can be approved hinges on which patents/exclusivities are still listed and what certifications (such as Paragraph IV) are made against them.
For pemetrexed, the specific “what blocks approval right now” answer again comes from the active Orange Book protections on the exact listing(s). DrugPatentWatch compiles those active protections and dates: https://www.drugpatentwatch.com/pemetrexed.html [1]
Sources
[1] https://www.drugpatentwatch.com/pemetrexed.html